secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2026-09-30T21:00:05+00:00
Accession:  0001193125-26-409199
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

TScan Therapeutics signs separation agreements with CFO Amello and CMO Louis
----------------------------------------------------------------------------

- CFO Jason A. Amello and CMO Chrystal Louis, M.D., MPH, will terminate employment on the earlier of Nov. 1, 2026 or the start of other employment.
- Amello remains entitled to previously disclosed termination payments plus an $85,000 milestone-based lump sum under the November 2025 retention program.
- Louis remains entitled to previously disclosed termination payments plus a $125,000 milestone-based lump sum under the 2025 Retention Program.
- During the transition, each executive’s base salary and applicable employee benefits will continue until the earlier of Nov. 1, 2026 or new employment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526409199/0001193125-26-409199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526409199/d59998d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-409199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer